Zenas BioPharma
Zenas is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. The company is advancing several advanced-stage drug candidates and is committed to innovation in immunology and autoimmune diseases.
Zenas BioPharma is a biotechnology company focused on discovering and developing therapies for autoimmune and inflammatory diseases. Their stated mission is “Enabling patients with autoimmune diseases to reimagine life,” and they concentrate on finding I&I (inflammation & immunology) innovations. Zenas advances novel drug candidates through discovery and development with the goal of bringing new treatment options to patients and partnering across the biopharma ecosystem.
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Share Price Swings
1 day ago
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 weeks ago
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.
Jan 5, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Zenas BioPharma.
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4
3 weeks ago
Senior Manager of Regulatory Documentation and Operations, Pulmovant
Pulmovant
Senior Specialist, Regulatory Operations
Summit Therapeutics,
Manager - Regulatory Dossier Services
Elanco
Submission Content Manager, Regulatory Affairs Operations
Olema Oncology
Associate Director, Regulatory Operations (EMEA)
Ultragenyx
Director/Senior Director, Regulatory Affairs, Pulmovant
Pulmovant